Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00464555 · ClinicalTrials.gov registry record · Phase 2
Strategies to Improve Islet Survival
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00464555 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 5 participants.
The verdict
NCT00464555, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control. The purpose of this study is to determine the safety and effectiveness of islet transplantation, combined with immunosuppressive medications and medications to support islet survival, for treating type 1 diabetes in individuals experiencing hypoglycemia unawareness and severe hypoglycemic episodes.
Interventions
- DRUG Sirolimus
- DRUG Basiliximab
- DRUG Antithymocyte globulin
- PROCEDURE Islet transplant
- DRUG Lisofylline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2006-12 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00464555
The ClinicalTrials.gov registry entry for NCT00464555 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Sirolimus is the first listed.
NCT00464555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00464555 about?
NCT00464555 is a clinical study titled "Strategies to Improve Islet Survival". Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control. The purpose of this study is to determine the safety and effectiveness of islet transplantation, combined with immunosuppressive medications and medicat...
What is the current status of trial NCT00464555?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2006-12. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00464555?
The interventions under investigation include: Sirolimus (DRUG), Basiliximab (DRUG), Antithymocyte globulin (DRUG), Islet transplant (PROCEDURE), Lisofylline (DRUG).
Who is sponsoring clinical trial NCT00464555?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.